Canagliflozin in Patients With Acute Decompansted Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.
Also called NCT05364190
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 142 participants
- Registry
-
NCT05364190
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT05364190. Randomized; no masking; primary purpose treatment. Start 2022-06-04 (actual); primary completion 2023-12-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Canagliflozin in Patients With Acute Decompansted Heart Failure
- Acronym
- The CANA -AHF
- Condition
- Chronic Heart Failure
- Condition
- Acute Heart Failure
- Condition
- Diabetes Mellitus
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- October 6 University
- Collaborator
- Cairo University
- Collaborator
- National Heart Institute, Egypt
Record details
- Record id
cardio:ct-nct05364190- Content hash
e70d6bab7438f684088a16000af4e7ee22318a3cde89cb8eef1749b573b80b55